PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

CA THE	Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
					Application Number	10/64	49,873	
					Filing Date	Augu	ıst 28, 2003	
;					First Named Inventor	PELI	ED Amnon et al	
					Art Unit	1632		
					Examiner Name			
Sheet		<u> </u>	of		Attorney Docket Number	2673	2	
			U.S.	PATENT	DOCUMENTS			
Examiner Initials*	Cite No. 1	Document Number		ation Date D-YYYY	Name of Patentee or Applicant of Cited Docume	nt	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
7377	ļ	Number-Kind Code ^{2 (If thown)}						
BH	1 1	US-2004/0171552	02-2-20	<u>04</u>	Peled et al.			
	<u> </u>		ļ					
		<u> </u>						
					<u> </u>			
					L			
· · · · · · · · · · · · · · · · · · ·	1							
	1							
	1							
	·	•	•		· · · · · · · · · · · · · · · · · · ·			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Documents Country Code ¹ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
ВН	2	PCT WO 03/072599	04-4-2003	Peled et al.		
ВН	3	PCT WO 02/061087	08-8-2002	Burmer et al.		
Examiner Signature		/Bruce Hissong/	I	Date Considered	10/27/200	6

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

*For Japanese asked documents, the indication of the voice of the prior of the spins of the spin *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue nublisher, etily and/or country where published. BH 4 Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab proudfoot et al. "The Strategy of Blocking the Chemokine System to Comba Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. 6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils I", The Journal of Immunology, 1 824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing I/AIDS Infection and Progression", The American Society for Biochemistry Molecular Biology, P.1-38, 2003.	e if Known				
STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT Examiner Initials No.¹ BH Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab Sheet Proudfoot et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From B and Activating Human Blood Neutrophils 1", The Journal of Immunology, 1 824, 1995. Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry	10/649				
STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT Examiner Initials No.¹ BH Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab Sheet Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils I", The Journal of Immunology, 1 824, 1995. Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry		28, 2003			
(use as many sheets as necessary) Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT Examiner Initials No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), to item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published. BH Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils 1", The Journal of Immunology, 1 824, 1995. Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry		Amnon et al			
Sheet Of OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT Examiner Initials No.¹ BH Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From B and Activating Human Blood Neutrophils I", The Journal of Immunology, I 824, 1995. Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry	26732				
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENT Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), to item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published. BH 4 Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab 5 Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. 6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Barand Activating Human Blood Neutrophils I", The Journal of Immunology, 1 824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Virus 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry					
Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), to item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number publisher, city and/or country where published. BH					
Initials No.¹ item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published. BH 4 Burmer et al. "G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab 5 Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. 6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils 1", The Journal of Immunology, 1 824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry	3				
No.944", Retrieved From EBI Database Accession No.ABP82271, 2003. Ab Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combar Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils I", The Journal of Immunology, 1 824, 1995. Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry	e of the aber(s),	T²			
Disease", Immunological Reviews, 177: 247-256, 2000. P.253-255. 6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Be and Activating Human Blood Neutrophils I", The Journal of Immunology, 1 824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing I/AIDS Infection and Progression", The American Society for Biochemistry	Antigenic Peptide SEQ ID				
6 Hayashi et al. "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 From Bi and Activating Human Blood Neutrophils I", The Journal of Immunology, I 824, 1995. 7 Misumi et al. "A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing I/AIDS Infection and Progression", The American Society for Biochemistry	5 Proudfoot et al. "The Strategy of Blocking the Chemokine System to Combat				
the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 as A Novel Human Immunodeficiency Virus Type 1 Vaccine", Journal of Vi 75(23): 11614-11620, 2001. 8 Misumi et al. "A Novel Cyclic Peptide Immunization Strategy for Preventing 1/AIDS Infection and Progression", The American Society for Biochemistry	4: 814-				
1/AIDS Infection and Progression", The American Society for Biochemistry	CCR5 ology,				

	/P		10/27/2006
Signature	/Bruce Hissong/	Considered	10,0,,,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.